patent.fyi
Applications  /  US 2026/0355104
United States Patent Application Publication

US 2026/0355104 A1

Published
Nov 12, 2026
Filed
Aug 30, 2024
Earliest date on the face
Aug 31, 2023
Classification
A61K 8/9789
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Niacinamide for uneven pigmentation

What ifWhat if the emulsion uses niacinamide?
Claim language“extract of Reynoutria japonica”

Dissolve 4% by weight niacinamide in the aqueous phase of an oil-in-water emulsion. Niacinamide reduces melanosome transfer from melanocytes to keratinocytes.

1.1Ascorbic acid for antioxidant activity

What ifWhat if the preparation uses ascorbic acid?
Claim language“extract of Reynoutria japonica”

Dissolve ascorbic acid in the aqueous phase at pH 3.2 to 3.5 and fill the formulation into an opaque airless dispenser. Ascorbic acid donates electrons to reactive species, and the dispenser limits exposure to oxygen and light during use.

1.1Acetyl glucosamine for uneven pigmentation

What ifWhat if the cream uses N-acetylglucosamine?
Claim language“extract of Reynoutria japonica”

Dissolve 2% by weight N-acetylglucosamine in the water phase before emulsification. N-acetylglucosamine interferes with the glycosylation and maturation of tyrosinase, an enzyme involved in melanin synthesis.

1.1Glycerol for stratum corneum hydration

What ifWhat if the cream uses glycerol?
Claim language“sodium mannose phosphate”

Blend 5% by weight glycerol into the continuous aqueous phase of an oil-in-water cream. Glycerol acts as a humectant and increases water retention in the stratum corneum.

1.1Petrolatum for reduced water loss

What ifWhat if the cream uses petrolatum?
Claim language“sodium mannose phosphate”

Disperse 10% by weight petrolatum in the heated oil phase before emulsifying it into the aqueous phase. After application, the deposited petrolatum forms an occlusive film that slows evaporation from the skin.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Parameter or scale variation

Single dose lotion fill sizes

A single oil-in-water lotion batch contains all eight ingredients and supplies two fill sizes. A piston filler dispenses 0.5 g into sachets for localized application and 2.0 g into larger sachets for application over a wider area. The filler operates from an agitated hopper, and an inline checkweigher verifies net fill mass for each format.

Automated or data-driven variant

Assay corrected dosing of ingredient concentrates

Batch software stores the target mass and measured lot concentration of each of the eight ingredient concentrates. It divides each target ingredient mass by the corresponding measured mass fraction to generate dispensing setpoints. Small concentrates are weighed into tared vessels on a precision balance, and larger additions are metered using load cells under the mixing vessel. The controller records each actual addition and holds the batch for review when a dose falls outside its configured tolerance.

Specific version of a part

Bisabolol in an ester phase

Dissolve 0.2% by weight alpha-bisabolol in caprylic and capric triglycerides. Add the resulting oil blend to an oil-in-water emulsion during cool-down and mix until uniform.

Oryzanol in dispersed oil droplets

Dissolve gamma-oryzanol in the heated oil phase at 0.1% by weight of the finished cream. Homogenize the oil phase into the aqueous phase with a nonionic emulsifier to disperse the dissolved material in oil droplets.

Sodium pyruvate in a gel

Dissolve sodium pyruvate in purified water at 0.5% by weight of the finished gel. Add the solution to hydrated hydroxyethylcellulose and adjust the final pH to 5.5.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2008/0300301 A1
Published
Dec 4, 2008
Filed
May 30, 2005
Class
A61K 31/353
Document BUS 11,351,146 B2
Published
Jun 7, 2022
Filed
Sep 3, 2018
Class
A61K 31/353
Claim 1
Document A
Document B
1.1bisabolol, oryzanol, extract of Reynoutria japonica, chrysin, quercetin, sodium mannose phosphate, kaempferol and pyruvate.
Disclosed is a composition for promoting a production of hyaluronic acid containing at least one of kaempferol and quercetin.
A · US 2008/0300301 A1 · abstract
A composition comprising a combination of a (halogenoacetamido)benzoate, a flavonol and a terpene, wherein the (halogenoacetamido)benzoate is ethyl 3-(2-chloroacetamido)benzoate or ethyl 3-(2-bromooacetamido)benzoate, the flavonol is selected from the group consisting of quercetin, kaempferol, dihydroquercetin, dihydrokaempferol, and mixture thereof, the terpene is selected from the group consisting of linanol, bisabolol, beta caryophyllene and a mixture thereof.
B · US 11,351,146 B2 · claim 1

An empty cell means only that no passage was reproduced there.

Statements in these documents
The present invention relates to a composition for promoting a production of hyaluronic acid containing at least one of kaempferol and quercetin.
A · US 2008/0300301 A1 · ¶ 1
When there occurs a degenerative arthritis, the generation of the hyaluronic acid serving as a lubricant in the joint is decreased and destructions by a proteolytic enzyme are increased to decrease the hyaluronic acid in the joint.
A · US 2008/0300301 A1 · ¶ 4
In particular, the present invention relates to a composition comprising an (halogenoacetamido)benzoate, a flavonol and a terpene for the use in the treatment of leishmaniasis, especially topical treatment of cutaneous leishmaniasis.
B · US 11,351,146 B2 · ¶ 2
However, they can last for months or years and typically result in scarring.
B · US 11,351,146 B2 · ¶ 7
Cite aspatent.fyi, US 2026/0355104 A1, claim 1, first published 2026-11-19T07:53:10-05:00, https://patent.fyi/US20260355104/, SHA-256 0b108eb9f9e3feaa6ef2e4c98caa7180e9fb121cfb02753ba72f6a714b4b88e5
First published
Permanent addresshttps://patent.fyi/US20260355104/
Content fingerprint (SHA-256)0b108eb9f9e3feaa6ef2e4c98caa7180e9fb121cfb02753ba72f6a714b4b88e5
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi